A detailed history of Pathstone Family Office, LLC transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, Pathstone Family Office, LLC holds 17,390 shares of ABCL stock, worth $51,300. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,390
Previous 14,924 16.52%
Holding current value
$51,300
Previous $96,000 17.71%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 08, 2023

BUY
$4.6 - $7.95 $11,343 - $19,604
2,466 Added 16.52%
17,390 $79,000
Q2 2023

Jan 12, 2024

SELL
$5.66 - $7.59 $13,957 - $18,716
-2,466 Reduced 14.18%
14,924 $96,000
Q2 2023

Aug 14, 2023

SELL
$5.66 - $7.59 $5,105 - $6,846
-902 Reduced 5.7%
14,924 $96,000
Q1 2023

May 15, 2023

SELL
$7.31 - $11.18 $12,880 - $19,699
-1,762 Reduced 10.02%
15,826 $119,000
Q4 2022

Oct 23, 2023

SELL
$9.48 - $14.52 $3,431 - $5,256
-362 Reduced 2.02%
17,588 $178,000
Q4 2022

Feb 13, 2023

SELL
$9.48 - $14.52 $3,431 - $5,256
-362 Reduced 2.02%
17,588 $178,000
Q3 2022

Oct 23, 2023

SELL
$9.2 - $13.68 $6,853 - $10,191
-745 Reduced 3.99%
17,950 $177,000
Q3 2022

Nov 14, 2022

SELL
$9.2 - $13.68 $6,853 - $10,191
-745 Reduced 3.99%
17,950 $178,000
Q2 2022

Oct 23, 2023

BUY
$5.72 - $10.65 $21,570 - $40,161
3,771 Added 25.27%
18,695 $199,000
Q2 2022

Aug 15, 2022

BUY
$5.72 - $10.65 $23,892 - $44,485
4,177 Added 28.77%
18,695 $199,000
Q1 2022

May 16, 2022

BUY
$7.46 - $14.14 $10,630 - $20,149
1,425 Added 10.88%
14,518 $142,000
Q4 2021

Feb 14, 2022

BUY
$12.99 - $17.73 $14,289 - $19,503
1,100 Added 9.17%
13,093 $187,000
Q3 2021

Nov 16, 2021

BUY
$14.85 - $21.34 $178,096 - $255,930
11,993 New
11,993 $240,000

Others Institutions Holding ABCL

About AbCellera Biologics Inc.


  • Ticker ABCL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 285,139,008
  • Market Cap $841M
  • Description
  • AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...
More about ABCL
Track This Portfolio

Track Pathstone Family Office, LLC Portfolio

Follow Pathstone Family Office, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pathstone Family Office, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pathstone Family Office, LLC with notifications on news.